10-K: Lantheus Holdings Reports Strong 2023 Results, Navigates Leadership Transition and Strategic Partnerships

Lantheus Holdings announces a CEO succession plan, strategic agreements with Perspective Therapeutics, and positive topline results for PNT2002, while navigating a complex regulatory and competitive landscape.

Summary

• Lantheus Holdings, a radiopharmaceutical-focused company, reported its 10-K filing for the fiscal year ended December 31, 2023.
• The company announced a CEO succession plan, with Brian Markison succeeding Mary Anne Heino effective March 1, 2024.
• Lantheus entered into strategic agreements with Perspective Therapeutics, including an option to license Pb212-VMT-NET and co-develop prostate cancer therapies, with an upfront payment of $28 million.
• Lantheus Alpha purchased 56,342,355 shares of Perspectives common stock for approximately $20.8 million, holding approximately 10.74% of Perspectives common stock.
• The company has exclusive worldwide rights (excluding certain Asian countries) to co-develop and commercialize POINT's PNT2002 and PNT2003 product candidates.
• PNT2002's SPLASH trial met its primary endpoint, demonstrating a median radiographic progression-free survival (rPFS) of 9.5 months compared to 6.0 months for the control arm.
• An Expanded Access Program (EAP) for PNT2002 is expected to enroll its first patient in the first quarter of 2024.
• Lantheus' ANDA for Lutetium Lu 177 Dotatate (177Lu-PNT2003) has been accepted for filing by the FDA.
• Advanced Accelerator Applications USA, Inc. and Advanced Accelerator Applications SA, each a Novartis entity, sued Lantheus for patent infringement in response to the ANDA filing.
• Lantheus acquired Cerveau Technologies, Inc. for an upfront payment of $35.0 million and an additional $10.0 million upon successful completion of a technology transfer.
• The company's commercial products are classified into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue.
• PYLARIFY is the leading radiopharmaceutical diagnostic agent indicated for PET imaging of PSMA-positive lesions in men with prostate cancer.
• The company estimates the current market potential for PSMA PET imaging agents in the U.S. for 2024 could be about 445,000 scans, and the total addressable market by 2029 could be over 700,000 annual scans.
• As of December 31, 2023, Lantheus had activated 54 PMF manufacturing sites in its PMF network.
• DEFINITY is the leading ultrasound enhancing agent in the U.S., with an estimated over 80% share of the U.S. segment for ultrasound enhancing agents in echocardiography procedures.
• TechneLite had approximately one third of the U.S. generator market as of December 31, 2023, competing primarily with Tc-99m-based generators produced by Curium.
• On August 2, 2023, Lantheus sold its right to its RELISTOR net sales royalties under its license agreement with Bausch and retained the rights to future sales-based milestone payments.
• During the fourth quarter of 2023, the Company earned the $15.0 million sales-based milestone payment related to RELISTOR.
• The company invested $77.7 million in research and development (R&D) in 2023.
• The company had 834 employees as of December 31, 2023.
• The company is subject to various federal, state and local laws and regulations relating to the protection of the environment, human health and safety.
• As of December 31, 2023, the company currently estimates the D&D cost of all of its manufacturing sites to be approximately $25.1 million.
• As of December 31, 2023 and 2022, the company has a liability of approximately $22.9 million and $22.5 million, respectively associated with its asset retirement obligations.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, strategic partnerships, and advancements in clinical development programs. However, it also acknowledges risks and challenges, such as competition, regulatory hurdles, and potential delays.

Positives

• Positive topline results from the SPLASH trial for PNT2002.
• FDA acceptance for filing of the ANDA for Lutetium Lu 177 Dotatate (177Lu-PNT2003).
• Continued growth of PYLARIFY and DEFINITY sales.
• Strategic agreements with Perspective Therapeutics and POINT Biopharma Global Inc.
• Acquisition of Cerveau Technologies, Inc.
• Sale of RELISTOR royalty asset generating immediate cash.
• Strong cash position of $713.7 million as of December 31, 2023.
• Continued efforts to expand strategic partnerships and develop innovative imaging biomarker solutions.

Negatives

• Patent infringement lawsuit filed by Advanced Accelerator Applications USA, Inc. and Advanced Accelerator Applications SA, each a Novartis entity, in response to the ANDA filing for PNT2003.
• Potential loss of TPT Status for PYLARIFY at the end of 2024.
• Dependence on third-party suppliers for Mo-99 and other raw materials.
• Competition from other PSMA PET imaging agents and ultrasound enhancing agents.
• Risks associated with the development and commercialization of PNT2002, PNT2003, MK-6240, and other clinical development candidates.
• Risks related to outstanding indebtedness and ability to satisfy obligations.
• Dependence on a limited number of large customers for a majority of revenues for SPECT nuclear medical imaging products.

Risks

• Ability to continue to grow PYLARIFY and DEFINITY sales.
• Dependence on third-party suppliers for Mo-99 and other raw materials.
• Competition from other PSMA PET imaging agents and ultrasound enhancing agents.
• Risks associated with the development and commercialization of PNT2002, PNT2003, MK-6240, and other clinical development candidates.
• Risks related to outstanding indebtedness and ability to satisfy obligations.
• Dependence on a limited number of large customers for a majority of revenues for SPECT nuclear medical imaging products.
• Potential delays or withdrawals of FDA approval for manufacturing sites.
• Uncertainties regarding reimbursement and regulation, including the impact of healthcare reform measures.
• Potential product liability claims and lawsuits.
• Cybersecurity threats and disruptions to information technology infrastructure.
• Dependence on partners for the development of certain product candidates.
• Risks associated with international economic, political, and other factors.

Future Outlook

The company expects to continue to grow PYLARIFY and DEFINITY sales, advance its clinical development programs, and pursue strategic partnerships and acquisitions to drive future growth. The company anticipates commercialization of flurpiridaz by GE Healthcare beginning in the second half of 2024.

Management Comments

• Brian Markison will become CEO effective March 1, 2024, succeeding Mary Anne Heino.

Industry Context

The radiopharmaceutical industry is evolving strategically, with several market participants recently sold. The supply-demand dynamics of the industry are complex because of large market positions of some participants, legacy businesses, government subsidies, and group purchasing arrangements.

Comparison to Industry Standards

• PYLARIFY competes with Gallium-68 (Ga-68)-based PSMA imaging agents from Telix Pharmaceuticals Limited and Novartis AG and an F 18 PSMA PET imaging agent from Blue Earth, as well as other non-PSMA-based imaging agents commonly referred to as conventional imaging.
• DEFINITY currently competes with ultrasound enhancing agents produced by GE Healthcare and Bracco.
• For a number of SPECT radiopharmaceutical commercial products, competitors currently include Curium, GE Healthcare, Bracco and Jubilant Life Sciences, an affiliate of JHS and Jubilant Radiopharma, and potentially BWXT Medical.
• For PNT2002 and 1095, principal competitors may include Novartis AG; Telix Pharmaceuticals Limited; and Curium, each of which has commercialized products or product candidates in advanced clinical stage of development.
• For PNT2003, principal competitor may include Novartis AG; ITM Radiopharma; and RayzeBio (under agreement to be acquired by Bristoll Meyers Squibb), each of which has commercialized products or product candidates in advanced clinical stage development.
• For MK-6240, principal competitors may include Eli Lilly and Company and Life Molecular Imaging, each of which has commercialized products or product candidates in advanced clinical stage of development.
• For LNTH-1363S, principal competitors may include Sofie Bioscience; GE Healthcare; and Novartis AG, each of which has product candidates in clinical stage of development.

Management Changes

Legal Proceedings

• Advanced Accelerator Applications USA, Inc. and Advanced Accelerator Applications SA, each a Novartis entity, sued Lantheus for patent infringement in response to the ANDA filing for PNT2003.

Stakeholder Impact

• Shareholders: Potential for increased value through successful product development and commercialization.
• Employees: Leadership transition and potential changes in strategic direction.
• Customers: Access to innovative diagnostic and therapeutic products.
• Patients: Improved diagnostic information and treatment options.
• Suppliers: Continued relationships for raw materials and manufacturing.
• Creditors: Ability to meet debt obligations and maintain financial stability.

Next Steps

• Continue commercialization efforts for PYLARIFY and DEFINITY.
• Advance clinical development programs for PNT2002, PNT2003, MK-6240, and LNTH-1363S.
• Pursue strategic partnerships and acquisitions to expand the product portfolio.
• Monitor and manage the Mo-99 supply chain.
• Address the patent infringement lawsuit related to PNT2003.
• Continue advocacy efforts with CMS and private insurers for appropriate reimbursement following the expiration of TPT Status.

Key Dates

Keywords

PYLARIFY, DEFINITY, PNT2002, PNT2003, MK-6240, TechneLite, Radiopharmaceutical, Oncology, Diagnostics, Lantheus, FDA, Clinical Trials, Reimbursement, Mo-99, PSMA, PET Imaging